283 related articles for article (PubMed ID: 36406250)
21. Microdroplet fluorochromatic assay for the enumeration of white cells (WBCs) in WBC-reduced blood components: validation and application for evaluating newly developed WBC-reduction filters.
Borzini P; Dumont LJ
Transfusion; 1997 Jun; 37(6):601-6. PubMed ID: 9191820
[TBL] [Abstract][Full Text] [Related]
22. Polybutylcyanoacrylate nanocarriers as promising targeted drug delivery systems.
Gao S; Xu Y; Asghar S; Chen M; Zou L; Eltayeb S; Huo M; Ping Q; Xiao Y
J Drug Target; 2015; 23(6):481-96. PubMed ID: 25738991
[TBL] [Abstract][Full Text] [Related]
23. Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG.
Pellegrino D; Bonab AA; Dragotakes SC; Pitman JT; Mariani G; Carter EA
J Nucl Med; 2005 Sep; 46(9):1522-30. PubMed ID: 16157536
[TBL] [Abstract][Full Text] [Related]
24. Cell membrane-camouflaged PLGA biomimetic system for diverse biomedical application.
Yan J; Fei W; Song Q; Zhu Y; Bu N; Wang L; Zhao M; Zheng X
Drug Deliv; 2022 Dec; 29(1):2296-2319. PubMed ID: 35861175
[TBL] [Abstract][Full Text] [Related]
25. Quality control of white cell-reduced red cells: white cell preservation and simplified counting.
Tran K; Nakajo S; Kapoor V; Chen M; Stromberg RR
Transfusion; 1998 May; 38(5):429-33. PubMed ID: 9633554
[TBL] [Abstract][Full Text] [Related]
26. Recent progress on charge-reversal polymeric nanocarriers for cancer treatments.
Sun Q; Zhu Y; Du J
Biomed Mater; 2021 May; 16(4):. PubMed ID: 33971642
[TBL] [Abstract][Full Text] [Related]
27. The effects of leukocytes on blood flow in a model skeletal muscle capillary network.
Warnke KC; Skalak TC
Microvasc Res; 1990 Jul; 40(1):118-36. PubMed ID: 2398826
[TBL] [Abstract][Full Text] [Related]
28. Engineering cancer cell membrane-camouflaged metal complex for efficient targeting therapy of breast cancer.
Li X; Yu Y; Chen Q; Lin J; Zhu X; Liu X; He L; Chen T; He W
J Nanobiotechnology; 2022 Sep; 20(1):401. PubMed ID: 36064356
[TBL] [Abstract][Full Text] [Related]
29. Dynamic Synthetic Biointerfaces: From Reversible Chemical Interactions to Tunable Biological Effects.
Ma Y; Tian X; Liu L; Pan J; Pan G
Acc Chem Res; 2019 Jun; 52(6):1611-1622. PubMed ID: 30793586
[TBL] [Abstract][Full Text] [Related]
30. Research update on cell membrane camouflaged nanoparticles for cancer therapy.
Wang C; Wu S
Front Bioeng Biotechnol; 2022; 10():944518. PubMed ID: 35992357
[TBL] [Abstract][Full Text] [Related]
31. Absorption, distribution, metabolism, and excretion of nanocarriers in vivo and their influences.
Zhang A; Meng K; Liu Y; Pan Y; Qu W; Chen D; Xie S
Adv Colloid Interface Sci; 2020 Oct; 284():102261. PubMed ID: 32942181
[TBL] [Abstract][Full Text] [Related]
32. Quantitation of residual white cells in filtered blood components by polymerase chain reaction amplification of HLA DQ-A DNA.
Lee TH; Stromberg RR; Heitman J; Tran K; Busch MP
Transfusion; 1994; 34(11):986-94. PubMed ID: 7974708
[TBL] [Abstract][Full Text] [Related]
33. Cell membrane camouflaged biomimetic nanoparticles: Focusing on tumor theranostics.
Zhu L; Zhong Y; Wu S; Yan M; Cao Y; Mou N; Wang G; Sun D; Wu W
Mater Today Bio; 2022 Mar; 14():100228. PubMed ID: 35265826
[TBL] [Abstract][Full Text] [Related]
34. Cell membrane engineering with synthetic materials: Applications in cell spheroids, cellular glues and microtissue formation.
Amaral AJR; Pasparakis G
Acta Biomater; 2019 May; 90():21-36. PubMed ID: 30986529
[TBL] [Abstract][Full Text] [Related]
35. Biomimetic approaches for targeting tumor-promoting inflammation.
Parodi A; Kostyushev D; Brezgin S; Kostyusheva A; Borodina T; Akasov R; Frolova A; Chulanov V; Zamyatnin AA
Semin Cancer Biol; 2022 Nov; 86(Pt 2):555-567. PubMed ID: 35472397
[TBL] [Abstract][Full Text] [Related]
36. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review.
Lossinsky AS; Shivers RR
Histol Histopathol; 2004 Apr; 19(2):535-64. PubMed ID: 15024715
[TBL] [Abstract][Full Text] [Related]
37. Cell membrane biomimetic nanoparticles for inflammation and cancer targeting in drug delivery.
Wang H; Liu Y; He R; Xu D; Zang J; Weeranoppanant N; Dong H; Li Y
Biomater Sci; 2020 Jan; 8(2):552-568. PubMed ID: 31769765
[TBL] [Abstract][Full Text] [Related]
38. The impact of nanocarriers in the induction of antigen-specific immunotolerance in autoimmune diseases.
Dangkoub F; Sankian M; Tafaghodi M; Jaafari MR; Badiee A
J Control Release; 2021 Nov; 339():274-283. PubMed ID: 34600024
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in erythrocyte membrane-camouflaged nanoparticles for the delivery of anti-cancer therapeutics.
Wang S; Wang Y; Jin K; Zhang B; Peng S; Nayak AK; Pang Z
Expert Opin Drug Deliv; 2022 Aug; 19(8):965-984. PubMed ID: 35917435
[TBL] [Abstract][Full Text] [Related]
40. Current issues of RNAi therapeutics delivery and development.
Haussecker D
J Control Release; 2014 Dec; 195():49-54. PubMed ID: 25111131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
